CORDIS
EU research results

CORDIS

English EN

Embryonic Stem cell-based Novel Alternative Testing Strategies

Project information

Grant agreement ID: 201619

Status

Closed project

  • Start date

    1 April 2008

  • End date

    30 September 2013

Funded under:

FP7-HEALTH

  • Overall budget:

    € 15 592 219,98

  • EU contribution

    € 11 895 577

Coordinated by:

KLINIKUM DER UNIVERSITAET ZU KOELN

Germany

Objective

"ESNATS aims at developing a novel toxicity test platform based on embryonic stem cells (ESC), especially human ESC (hESC), to accelerate drug development, reduce R&D costs and propose a powerful alternative to animal tests (3 Rs). ESNATS will address current drug-testing shortcomings: - testing takes place late in the development cycle - animal test systems bear the risk of non-prediction due to inter-species variation - non-ESC assays rely on primary cells or cells of malignant origin that are hard-to-standardise and limited in regard to quantity, homogeneity and genetic diversity - existing assay systems based on primary animal cell lines do not reliably represent the physiological situation ESNATS will develop a battery of toxicity tests using hESC lines subjected to different standardised culture protocols. Tests will cover embryoid bodies in different developmental stages and differentiated derivatives including gamete and neuronal lineages, complemented with test systems for hepatic metabolism. Predictive toxicogenomics and proteomics markers will be identified. The individual tests will be integrated into an ""all-in-one"" test system. To enable future industrial use ESNATS will prepare automating and scaling up of hESC culture. The predictivity, quality and reproducibility of ESNATS will be evaluated in a proof of concept study. ESNATS benefits are to increase safety due to better predictivity of human test systems, to reduce, refine and replace animal tests, to lower testing cost, and to support medium/high throughput testing. ESNATS objectives will be achieved in a 5 year multi-disciplinary collaboration of leading European researchers in alternative testing, toxicology, ESC research, genomics, modelling, and automation. The consortium will also include representatives from regulatory bodies, the pharmaceutical industry and ethical advisors to provide guidance to ensure rapid applicability of the developed tests systems."

Coordinator

KLINIKUM DER UNIVERSITAET ZU KOELN

Address

Kerpener Strasse 62
50937 Koeln

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 825 955,59

Administrative Contact

Jutta Landvogt (Ms.)

Participants (32)

JRC -JOINT RESEARCH CENTRE- EUROPEAN COMMISSION

Belgium

EU Contribution

€ 604 973

UNIVERSITY OF NEWCASTLE UPON TYNE

United Kingdom

EU Contribution

€ 261 783,16

UNIVERSITE DE GENEVE

Switzerland

EU Contribution

€ 1 162 283

FORSCHUNGSGESELLSCHAFT FUR ARBEITSPHYSIOLOGIE UND ARBEITSSCHUTZ E.V.

Germany

EU Contribution

€ 1 056 023,75

EUROPEAN CONSENSUS PLATFORM ON 3R-ALTERNATIVES TO ANIMAL EXPERIMENTATION

Belgium

EU Contribution

€ 22 760

THE AUTOMATION PARTNERSHIP (CAMBRIDGE) LIMITED

United Kingdom

EU Contribution

€ 172 800

OU QURETEC

Estonia

EU Contribution

€ 501 400

PROTEOSYS AG

Germany

EU Contribution

€ 83 757

UNIVERSITE DE LIEGE

Belgium

EU Contribution

€ 50 455,70

CONSORZIO PER L'INCREMENTO ZOOTECNICO SRL

Italy

EU Contribution

€ 69 920

Takara Bio Europe AB

Sweden

EU Contribution

€ 485 595

CELL CURE NEUROSCIENCES LTD

Israel

EU Contribution

€ 176 400

UNIVERSITAT KONSTANZ

Germany

EU Contribution

€ 892 173

Public Health England an Executive Agency of the Dept of Health

United Kingdom

EU Contribution

€ 41 483,67

NEDERLANDSE ORGANISATIE VOOR TOEGEPAST NATUURWETENSCHAPPELIJK ONDERZOEK TNO

Netherlands

EU Contribution

€ 330 075

THE UNIVERSITY OF EDINBURGH

United Kingdom

EU Contribution

€ 743 670

VRIJE UNIVERSITEIT BRUSSEL

Belgium

EU Contribution

€ 636 294

KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN

Germany

EU Contribution

€ 103 439,25

ARTTIC

France

EU Contribution

€ 712 035

THE SCHOOL OF PHARMACY, UNIVERSITY OF LONDON

United Kingdom

EU Contribution

€ 1 974,54

N.V. ORGANON

Netherlands

LAKEMEDELSVERKET

Sweden

H. LUNDBECK AS

Denmark

IN VITRO TESTING INDUSTRIAL PLATFORM

Spain

BUNDESINSTITUT FUER RISIKOBEWERTUNG

Germany

EDINETHICS LIMITED

United Kingdom

EU Contribution

€ 36 000

GOTTFRIED WILHELM LEIBNIZ UNIVERSITAET HANNOVER

Germany

EU Contribution

€ 222 695

F. HOFFMANN-LA ROCHE AG

Switzerland

AVANTEA srl

Italy

EU Contribution

€ 397 328,80

BRUNEL UNIVERSITY LONDON

United Kingdom

EU Contribution

€ 148 025,46

EBERHARD KARLS UNIVERSITAET TUEBINGEN

Germany

EU Contribution

€ 46 560,75

Department of Health

United Kingdom

EU Contribution

€ 109 716,33

Project information

Grant agreement ID: 201619

Status

Closed project

  • Start date

    1 April 2008

  • End date

    30 September 2013

Funded under:

FP7-HEALTH

  • Overall budget:

    € 15 592 219,98

  • EU contribution

    € 11 895 577

Coordinated by:

KLINIKUM DER UNIVERSITAET ZU KOELN

Germany